↓ Skip to main content

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial

Overview of attention for article published in Frontiers in immunology, November 2020
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
2 news outlets
twitter
6 X users

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
72 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
Published in
Frontiers in immunology, November 2020
DOI 10.3389/fimmu.2020.595035
Pubmed ID
Authors

Nicolai Grønne Jørgensen, Uffe Klausen, Jacob Handlos Grauslund, Carsten Helleberg, Thomas Granum Aagaard, Trung Hieu, Shamaila Munir Ahmad, Lars Rønn Olsen, Tobias Wirenfeldt Klausen, Marie Fredslund Breinholt, Morten Hansen, Evelina Martinenaite, Özcan Met, Inge Marie Svane, Lene Meldgaard Knudsen, Mads Hald Andersen

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 72 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 10 14%
Student > Master 10 14%
Unspecified 8 11%
Researcher 7 10%
Student > Doctoral Student 3 4%
Other 7 10%
Unknown 27 38%
Readers by discipline Count As %
Medicine and Dentistry 10 14%
Unspecified 8 11%
Biochemistry, Genetics and Molecular Biology 7 10%
Agricultural and Biological Sciences 6 8%
Immunology and Microbiology 5 7%
Other 8 11%
Unknown 28 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 June 2022.
All research outputs
#1,578,844
of 26,163,973 outputs
Outputs from Frontiers in immunology
#1,429
of 33,001 outputs
Outputs of similar age
#39,845
of 441,969 outputs
Outputs of similar age from Frontiers in immunology
#68
of 873 outputs
Altmetric has tracked 26,163,973 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 33,001 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 441,969 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 873 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.